Use of Clinical Trial Characteristics to Estimate Costs of New Drug Development
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.53275
Abstract: Key Points Question What is the estimated cost to develop a new drug and how do research and development (R&D) costs vary across firms? Findings This economic evaluation examining 268 US-traded drug developers found that,… read more here.
Keywords: new drug; clinical trial; costs per; drug ... See more keywords
Temporal trends in acute care costs of hip fracture treatment from 2011 to 2021 in Japan
Sign Up to like & getrecommendations! Published in 2025 at "Archives of Osteoporosis"
DOI: 10.1007/s11657-025-01607-3
Abstract: We investigated annual trends in acute care costs for hip fracture treatment in Japan from 2011 to 2021. While gross medical costs and costs per hospitalization initially declined, both increased after 2013 and 2014, respectively.… read more here.
Keywords: hip fracture; costs per; medical costs; acute care ... See more keywords
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.22021
Abstract: BACKGROUND: Venetoclax, in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC), received confirmatory approval in 2020 by the US Food and Drug Administration for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients… read more here.
Keywords: per patient; ineligible intensive; costs per; newly diagnosed ... See more keywords